Infiltrating Mast Cell-Mediated Stimulation of Estrogen Receptor Activity in Breast Cancer Cells Promotes the Luminal Phenotype.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
01 06 2020
Historique:
received: 14 11 2019
revised: 04 02 2020
accepted: 11 03 2020
pubmed: 18 3 2020
medline: 12 11 2020
entrez: 18 3 2020
Statut: ppublish

Résumé

Tumor growth and development is determined by both cancer cell-autonomous and microenvironmental mechanisms, including the contribution of infiltrating immune cells. Because the role of mast cells (MC) in this process is poorly characterized and even controversial, we investigated their part in breast cancer. Crossing C57BL/6 MMTV-PyMT mice, which spontaneously develop mammary carcinomas, with MC-deficient C57BL/6-Kit

Identifiants

pubmed: 32179512
pii: 0008-5472.CAN-19-3596
doi: 10.1158/0008-5472.CAN-19-3596
doi:

Substances chimiques

Receptors, Estrogen 0
ErbB Receptors EC 2.7.10.1
Proto-Oncogene Proteins c-met EC 2.7.10.1
Receptor, ErbB-2 EC 2.7.10.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2311-2324

Informations de copyright

©2020 American Association for Cancer Research.

Auteurs

Maria Teresa Majorini (MT)

Molecular Immunology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Valeria Cancila (V)

Tumor Immunology Unit, Department of Health Sciences, Human Pathology Section, University of Palermo School of Medicine, Palermo, Italy.

Alice Rigoni (A)

Molecular Immunology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Laura Botti (L)

Molecular Immunology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Matteo Dugo (M)

Platform of Integrated Biology, Department of Applied Research and Technology Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Tiziana Triulzi (T)

Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Loris De Cecco (L)

Platform of Integrated Biology, Department of Applied Research and Technology Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Enrico Fontanella (E)

Molecular Immunology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Elena Jachetti (E)

Molecular Immunology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Elda Tagliabue (E)

Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Claudia Chiodoni (C)

Molecular Immunology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Claudio Tripodo (C)

Tumor Immunology Unit, Department of Health Sciences, Human Pathology Section, University of Palermo School of Medicine, Palermo, Italy.

Mario P Colombo (MP)

Molecular Immunology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. daniele.lecis@istitutotumori.mi.it mariopaolo.colombo@istitutotumori.mi.it.

Daniele Lecis (D)

Molecular Immunology Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. daniele.lecis@istitutotumori.mi.it mariopaolo.colombo@istitutotumori.mi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH